Published in Clin Infect Dis on March 19, 2012
The evaluation and diagnosis of "insomnia" in relation to sleep disturbance prevalence and impact in early-treated HIV-infected persons. Clin Infect Dis (2012) 0.91
HIV-associated neurocognitive disorders: the relationship of HIV infection with physical and social comorbidities. Biomed Res Int (2015) 0.89
HIV clades B and C are associated with reduced brain volumetrics. J Neurovirol (2013) 0.88
Sleep disturbances in persons living with HIV. J Assoc Nurses AIDS Care (2013) 0.85
Health correlates of co-occurring substance use for women with HIV in cocaine use recovery. Addict Behav (2013) 0.78
Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures. Int J Environ Res Public Health (2016) 0.75
Quality of Sleep in an HIV Population on Antiretroviral Therapy at an Urban Tertiary Centre in Lagos, Nigeria. Neurol Res Int (2014) 0.75
Engagement in Care, Psychological Distress, and Resilience are Associated with Sleep Quality among HIV-Positive Gay, Bisexual, and Other Men Who Have Sex with Men. Sleep Health (2016) 0.75
Electrolyte imbalance and sleep problems during anti-retroviral therapy: an under-recognized problem. Sleep Sci (2017) 0.75
Cytokine polymorphisms are associated with daytime napping in adults living with HIV. Sleep Med (2017) 0.75
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res (1989) 57.78
Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist (1969) 45.63
A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep (1991) 44.17
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA (1989) 10.82
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (2004) 4.90
Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med (2006) 3.87
Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep (1999) 3.74
Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry (1979) 2.60
Quality of life in people with insomnia. Sleep (1999) 1.67
Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. Psychosom Med (2005) 1.45
Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology (2005) 1.39
High prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.38
Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr (2001) 1.33
Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. Am J Psychiatry (1992) 1.20
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med (2006) 1.13
Somatic symptoms and HIV infection: relationship to depressive symptoms and indicators of HIV disease. Am J Psychiatry (1995) 1.09
Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis (2004) 1.07
Early central nervous system response to HIV infection: sleep distortion and cognitive-motor decrements. AIDS (1995) 1.04
Correlates of sleep quality in persons with HIV disease. J Assoc Nurses AIDS Care (2001) 1.01
Obstructive sleep apnoea among HIV patients. Int J STD AIDS (2006) 1.01
Sleep disturbances among HIV-positive adults: the role of pain, stress, and social support. J Psychosom Res (2004) 1.00
Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep (1992) 1.00
Sleep disturbances in HIV-seropositive patients. JAMA (1988) 0.95
Nocturnal sleep EEG in patients with HIV infection. Eur Arch Psychiatry Clin Neurosci (1991) 0.92
Sleep in men and women infected with human immunodeficiency virus. Holist Nurs Pract (1996) 0.92
Prevalence of insomnia and its psychosocial correlates among college students in Hong Kong. J Am Coll Health (2010) 0.92
A randomized crossover study to compare efavirenz and etravirine treatment. AIDS (2011) 0.91
Anthropometry in the prediction of sleep disordered breathing in HIV-positive and HIV-negative men. Antivir Ther (2010) 0.91
The pharmacologic management of insomnia in patients with HIV. J Clin Sleep Med (2009) 0.87
Self-reported sleep quality in HIV infection: correlation to the stage of infection and zidovudine therapy. J Acquir Immune Defic Syndr (1991) 0.86
Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. J Cardiometab Syndr (2008) 0.79
Severe insomnia related to high concentrations of raltegravir. AIDS (2011) 0.77
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64
Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr (2006) 5.87
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe (2008) 4.55
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS (2009) 4.02
Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis (2009) 3.92
Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis (2009) 3.48
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc (2004) 3.21
The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med (2007) 3.20
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol (2005) 2.87
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev (2009) 2.86
Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. Clin Infect Dis (2009) 2.50
The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell (2004) 2.46
Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis (2011) 2.44
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A (2008) 2.38
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS (2005) 2.25
Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol (2004) 2.22
Sex differences in learning in chimpanzees. Nature (2004) 2.22
Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis (2003) 2.16
Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Res (2006) 2.11
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health (2005) 2.02
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.91
Measurement and predictors of resilience among community-dwelling older women. J Psychiatr Res (2008) 1.91
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect (2004) 1.84
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
A longitudinal study of the use of mental health services by persons with serious mental illness: do Spanish-speaking Latinos differ from English-speaking Latinos and Caucasians? Am J Psychiatry (2007) 1.78
Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma (2011) 1.77
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr (2009) 1.70
HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One (2008) 1.69
Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS (2008) 1.69
Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke (2004) 1.68
Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr (2008) 1.66
Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol (2008) 1.64
Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm (2011) 1.64
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Provider factors associated with intramedullary nail use for intertrochanteric hip fractures. J Bone Joint Surg Am (2010) 1.62
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol (2005) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol (2010) 1.60
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS (2006) 1.55
Invasive mold infections following combat-related injuries. Clin Infect Dis (2012) 1.55
Associations of smoking prevalence with individual and area level social cohesion. J Epidemiol Community Health (2004) 1.53
A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull (2004) 1.53
ZIP-code-based versus tract-based income measures as long-term risk-adjusted mortality predictors. Am J Epidemiol (2006) 1.53
Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52
Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defic Syndr (2011) 1.52
Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics (2012) 1.46
Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr (2010) 1.46
Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J Neurochem (2013) 1.43
Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther (2006) 1.40
HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis (2010) 1.40
Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res (2003) 1.39
Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS (2010) 1.39
Body size and predatory performance in wolves: is bigger better? J Anim Ecol (2009) 1.36
Cleansing without compromise: the impact of cleansers on the skin barrier and the technology of mild cleansing. Dermatol Ther (2004) 1.33
Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. J Clin Exp Neuropsychol (2006) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Human brain glycogen metabolism during and after hypoglycemia. Diabetes (2009) 1.32
CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol (2008) 1.31
Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord (2010) 1.30
Neurocognitive impairment in middle-aged and older adults with bipolar disorder: comparison to schizophrenia and normal comparison subjects. J Affect Disord (2007) 1.29